Literature DB >> 23426118

Primary high-grade neuroendocrine carcinoma of the esophagus: a clinicopathologic and immunohistochemical study of 42 resection cases.

Qin Huang1, Hongyan Wu, Ling Nie, Jiong Shi, Abraham Lebenthal, Jieyu Chen, Qi Sun, Jun Yang, Lily Huang, Qing Ye.   

Abstract

Primary high-grade neuroendocrine carcinoma of the esophagus (HNCE) is rare and poorly understood. In this study, we aimed at delineating the clinicopathologic and immunohistochemical characteristics of HNCE diagnosed on the basis of the World Health Organization criteria for pulmonary neuroendocrine carcinomas. We identified 42 (3.8%) consecutive resection cases of HNCE among 1105 esophageal cancers over a 7-year period. Patients' mean age was 62 years (range, 47 to 79 y) with a male to female ratio of 3.7. Dysphagia was present in 79% of patients and tobacco abuse in 50%. Most tumors were centered in the middle (52%) or lower (36%) esophagus; 48% were ulcerated and 31% exophytic. All tumors were sharply demarcated with a pushing border in either solid sheet (83%) or nodular (17%) growth patterns. Pure HNCE was found in 57%, and the remainder also exhibited small components of squamous cell carcinoma (SqCC) or glandular, signet ring cell differentiations. SqCC in situ was present in 50%. Most tumors (88%) were the small cell type with pure oat-like cells in 52%, and the larger spindled, anaplastic, and giant cells were common. Tumor crush artifact (98%) and the Azzopardi effect (88%) were widespread. Extensive lymphovascular (50%) and perineural (33%) invasion and metastasis to regional (48%) and abdominal celiac lymph nodes (29%) were observed. Neoplastic cells were immunoreactive to synaptophysin (100%), CD56 (93%), chromogranin A (67%), p63 (55%), TTF-1 (71%), CK8/18 (90%), CD117 (86%), HER2 (16%), and p16 (84%) antibodies. The 5-year survival rate was 25%, similar to that of SqCC. Lymphovascular and perineural invasion was associated with a worse prognosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23426118     DOI: 10.1097/PAS.0b013e31826d2639

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  36 in total

Review 1.  Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

Authors:  Andrew M Bellizzi
Journal:  Hum Pathol       Date:  2019-12-17       Impact factor: 3.466

2.  Undifferentiated carcinoma of the esophagus: a clinicopathological study of 16 cases.

Authors:  Aatur D Singhi; Raja R Seethala; Katie Nason; Tyler J Foxwell; Robyn L Roche; Kevin M McGrath; Ryan M Levy; James D Luketich; Jon M Davison
Journal:  Hum Pathol       Date:  2014-12-17       Impact factor: 3.466

3.  Concurrent Lesions in Oesophagus: an Approach to Diagnosis with a Case Report.

Authors:  Yookarin Khonglah; Ankit Kumar Jitani; Bidyut Bikash Gogoi; Nobin Hage; L Purnima Devi; Kyrshanlang Giri Lynrah
Journal:  J Gastrointest Cancer       Date:  2017-06

4.  Primary Esophagogastric Neuroendocrine Carcinoma: a Retrospective Study from the Nottingham Upper Gastrointestinal Cancer Center.

Authors:  Constantinos Savva; Philip Kaye; Irshad Soomro; Simon L Parsons; Eleanor James; Srinivasan Madhusudan
Journal:  J Gastrointest Cancer       Date:  2018-03

5.  Validation and proposed modification of the 8th edition American Joint Committee on Cancer staging system for patients with esophageal neuroendocrine neoplasms: Evaluation of a revised lymph node classification.

Authors:  Haihong Wang; Yaobing Chen; Guoliang Pi; Ying Zhu; Shengli Yang; Hong Mei; Zhenyu Lin; Tao Zhang
Journal:  Oncol Lett       Date:  2020-03-27       Impact factor: 2.967

Review 6.  Neuroendocrine Tumors of the Esophagus: State of the Art in Diagnostic and Therapeutic Management.

Authors:  Dimitrios Schizas; Aikaterini Mastoraki; George I Kirkilesis; Athanasios D Sioulas; Ioannis S Papanikolaou; Evangelos P Misiakos; Nikolaos Arkadopoulos; Theodore Liakakos
Journal:  J Gastrointest Cancer       Date:  2017-12

7.  Small cell type neuroendocrine carcinoma colliding with squamous cell carcinoma at esophagus.

Authors:  Luoluo Yang; Xun Sun; Yabin Zou; Xiangwei Meng
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

8.  Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas.

Authors:  Z H Lu; J Li; M Lu; X T Zhang; J Li; J Zhou; X C Wang; J F Gong; J Gao; Y Li; L Shen
Journal:  Med Oncol       Date:  2013-07-18       Impact factor: 3.064

9.  Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection.

Authors:  Han-Yu Deng; Peng-Zhi Ni; Yun-Cang Wang; Wen-Ping Wang; Long-Qi Chen
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

10.  The Role of Surgery in Treating Resectable Limited Disease of Esophageal Neuroendocrine Carcinoma.

Authors:  Han-Yu Deng; Gang Li; Jun Luo; Xin-Rui Li; Guha Alai; Yi-Dan Lin
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.